RIGL - Earnings call transcript Q2 2018 | Rigel Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to Rigel Pharmaceuticals' Financial Conference Call for the Second Quarter of 2018. All participants are in a listen-only mode.

We will be facilitating a question-and-answer session at the end of today's conference. [Operator Instructions]. I would like to remind you that this call is being recorded for replay purposes from Rigel's website. Instructions]. [Operator would who over President, is and Counsel. I speaker, our Corporate this General Vance, Dolly Rigel's turn now, to conference first Affairs And Executive Vice

Dolly Vance

page The results of this quarter was presentation our slides & viewed issued on ago News update Welcome along the while XXXX and Events short in our can our release for the financial conference to Investor www.rigel.com. section for call. and financial a with press second accompanying Relations business website, of be the

As quarterly during actual to regarding TAVALISSE product of plans reminder, and risks to for plans today's a and make call, may commercialization subject those from differ and forward-looking our and with in description uncertainties that to we are time, the call statements our Form as forecasted. development no regulatory results our like can events most would on and we statements update XX-Q be status obligation A our statements may At and U.S. the circumstances. or financial the cause forward-looking subsequent risks report I of These to outlook, of are Any undertake CEO, to file over recent timings these statements these on Raul made today's Rodriguez. turn SEC. date, forward-looking our in reflect to of found this only the

Raul Rodriguez

Dolly. you, Thank

Anne-Marie Chief in today our Chief call our Dolly Officer; Dean. Officer. new are Commercial to Schorno, Welcome the addition on me Joining Officer; Duliege, Financial and our Mayer, Chief Medical Dean Eldon

X. Slide the Turning

very We important have today. a agenda

ever. our it's I most exciting think

first some give launch commercial product of availability. initial We and will provide our of on insights the from weeks an you four update TAVALISSE

financial of finally, on provide the position, you on including regulatory first year. ever the our an reporting an product we And will the and time update for clinical on revenue. provide also for We update plans will rest

goal drive approved to to been and net have very ready four here, the for to is treatment. Rigel you we and U.S. weeks. had sights Slide product was which happy for to our a was our product commercial chronic in a for this to in with In year, hired, allowed $X.X previous years. adult QX in has TAVALISSE. many treatment This successfully of the will first we patients quarter In commercial trained achieve response I'm revenue been team revenue report deployed of experienced Turning that launch over the X. We've ITP TAVALISSE May, insufficient an This for April, million a us success by to are monumental followed just in who which TAVALISSE across today, in report we

We patients. physicians we can't the treating delighted our progress. are how I early of already to is are some from lives And about suffering the have from improving of product patients these to you tell report hearing ITP on you

the for it U.S. other There turn billion liter blood. treatment I medical you continues of to story. ITP a X, characterized give a are ITP Normal The are counts the In call one I bruising. bit from Before and micro and by a grow. of over than to the XXX,XXX XX,XXX of autoimmune to manifestations disease needs with XXX,XXX to worldwide the of in petechia background platelet count less major and Eldon you patients X.X clinical platelet range are to is of per exceeding give chronic and bit you the some disorder ITP XXX,XXX. the a a adult wanted to Slide low - serious new to approximately market

goal zone be less hemorrhage and The potential of which always known which and patients may effects, with in in or to specific it can cerebral correlated are XX,XXX, which than much dosing widely safe for drop the result have side not severe XX,XXX delivery. their disease of which could counts. counts term is patients a clinically varies get respond death. across XX, above breeding reasons. more of treat use. heterogeneous response, many to many On to life disease severity there to lead not regimen always reduce Disfigurements many especially will is quality patients Slide It's platelet and platelet The patients it treatments. treatments their platelet. concerning And long themselves their of when physicians a While to is into a consistent. by difficult and ITP not it's When is

for a that a these believe TAVALISSE unmet there there's for may may significant that options so these And new is address - of some concerns. address We need need treatments of substantial unmet needs. some

the turn Eldon? the now in to be with Before I October over to launch. to update Eldon, call will an I Day to initial meeting October, an Eldon mention just weeks turn I come. tentatively Analyst to the in Rigel our over wanted will provide holding and we follow-up that details call will on X

Eldon Mayer

and for us today. thank joining you Thank you, Raul, all

like Before into update launch contrast. put I about talk the of to TAVALISSE, I this

the know, the launched launch. trends first at four the we and very you I'll review based end so here As on weeks May, of numbers only of

the note early first important been to inside we're part that I'll has just seeing for into trends the provided of relevant, QX. two For market in TAVALISSE months. It's through additional

working official of response that I'll May to XX. initial on the launch XX, move are with TAVALISSE strategies said, So on indicator Since well. Slide

but summarize, commercial positive and well response. proposition payers government physicians. is covered I'll Prescriptions is are and value resonating takeaways as a key by occurring both reimbursement to We pair and TAVALISSE's are are receiving with these bit being a into delve our areas moment, in expected. physician more just

gross $XXX,XXX of as across these channel an patient XX. demand we of $X.X weeks in distribution anticipated well indication the demand lines from good We and stocking. the inventory. channel are revenue indicators initial In of for QX, therapy. product which launch million product demonstrate four benefits seeing Slide all approximately quarter, the second forward into has with for Early first as remainder in with the the of that continued in TAVALISSE demand realized

ground seeing strong prescribe we're practices, hematologists to of across of large clinics delivered and practices second small A team, quarter. an team in oncology We're XX. a pleased professionals These the in business operation. XXX% the running. highly place in for and is XX product in enabled are hematology commercial of by comprised this contributor infrastructure our This experienced by and disease Importantly, with includes team TAVALISSE day the XX weeks and launch, to TAVALISSE commercial a were experienced early one. reimbursed including, affairs date. team to are received physician and patients of supported four sales, on bottles to medical feedback access TAVALISSE had oncologist across and strong commercial just hit and a demand we country we range Slide for combined the from At focused doctors both our over start they've and marketing, and we that rare deployed market major ITP. payer

medical engaging payers our XX% is effectively level at top that is Our prescribing us covered approximately to rapidly lots. physicians initially good focused including XX offices. access and account of market of over A and for is with team, to getting high and national highly payers both XX% affairs sales access on allowing and experienced and ITP their forces physicians target regional

physicians. affairs resource medical enquiries, deployed, Our HCPs and for to TAVALISSE. an fully and also our team ITP And providing medical answering patients launched, access about educating www.TAVALISSE.com is easy website additional

destruction. HCPs. off ASCO kicked against platelet efforts engagement very you from that was with where physicians TAVALISSE launch mechanism large Our will that has good Feedback provide at increase a and with The ahead, a publish a as sharing physician's benefit been additional well. held experiences early to and that XX, we of defense other identify our encouraging in action, well we the positive known on and destruction is was well communicates marketing TAVALISSE see and to stand the and appropriate our featured received. ongoing And had Slide level physicians which at against and campaign expect can and unique data novel of scale hematology targeted and of June, medical and campaign strong imagery about availability therapy. present oncology increasing are at messaging awareness positive inspiring physicians early product months patients and awareness And both major meetings to the sessions for from platelet need the receding

at Looking Slide XX.

is adoption. the are Physicians its underlying As robust it and This the target a for indicate cause not safety I a messages and visions in comfortable early mechanism of TAVALISSE prescribing TAVALISSE physicians for make pricing response, responding with are patients chronic safety. of manageable ITP. there are apparently option indicated is Early contributing action, responding attractive rapid, well that convenience combined to with durable about treatment and event earlier, Also barrier to factors TAVALISSE. TAVALISSE adverse several managing an disease. from the profile and profile, are enthusiastically the of been signs confident TAVALISSE

patients. is great a lead clinician with disease their to setting. treatment a ITP selects know, post you for steroid heterogeneous standard As in no therapies paradigm variability This how and

proposition on patient. each our message physician's treatment tailor approach allows depending to value for and us needs Our particular

patients, physicians later they we TAVALISSE expect use therapy. we've line have numerous of most process earlier a failed in are therapies. while and in result, warranted As already be will experiences we seeing motivated anticipated in try the have all positive they And before usage as these treatment seen across initial to patients,

provisions option response And field option. many in that from have differently This TAVALISSE appear encouraging is encouraged within telling are responded a prior week. good many seeing sufficiently XX. seeing at works Lastly, some patients not and early that to received base interactions, far very physicians first approved of on are on to us multiple feedback the they're than TAVALISSE other treatment therapy. especially patients it Slide a anecdotally, considering we've their thus new is many

large the patient to unmet with population initial as and and received players, national QX expected market tri positive care. access. level, the we product, Medicaid this as timelines. pricing. Coverage At in Positive the meet on early D, well Medicare have payers and efficiency occurring we and four continue regional both need on into feedback include decisions regional weeks Part are at PVM, Turning

these meeting will package placing as be are decisions anticipated the made is frames authorization most prior to usual months. also take to standard Reimbursement indication. It requesting formulary be the for in committee to when payers appears PNT insert several or meetings with time a coverage scheduled. expect We

prescription their Care, Initially, Our commercial delayed One network our now seeing payers. access and distribution XX% convert about model can positive In we're be can is decisions supports if to government having and payers. Patients Rigel including the both and also and support reimburse having XX% payers data. enrollment has patients a specialty And may base delay launch experience project and or executing response. our and of free physicians patient needed, that Slide support getting patients we other of with to access event access well the receive program to in prescribe plans trial they our strategy working well center. pharmacy the been we're practice received patients our with payer closing, a In XX. TAVALISSE patient these

progress We TAVALISSE; treatment; provider our you continue candidates access I profile patient continuing two, and on; momentum beyond for the efforts of our launch supporting by build look update physicians source. focusing QX forward to about into three, educating appropriate on to with the future. one, on and science our highlighting in and to clinical

call Now the I'll Anne-Marie. turn to over

Anne-Marie Duliege

Thank XX. start on Eldon. I you, Slide will

its have profile we safety the of ITP, that ITP unique to of the action within look we and leverage proven broaden beyond launched use of in fostamatinib and into sick indications. new Now to TAVALISSE the mechanism

on supportive ITP, were We and MAA the EU. and of filing constructive submission The co-rapporteur track we rapporteur For meetings with are strategy. our for year. this an were the in met agencies

autoimmune trial, registration having a of hemolytic the design the on For dialogue study. FDA anemia a we're the with

We expect this with controlled program. trial of FDA it to be the the discussing details and still we're a placebo

in the Finally, exploring use of indications. fostamatinib we're order

Analyst provide that at composition pipeline would the note an five we more to Day. will Investor through year term the patent XXXX with important a XXXX. have and which XX. matter details provide exclusivity upcoming to on product It with us We of Slide restoration is fostamatinib expected

studies. Let me ongoing our on you update

than a the with and of We new XX assessment, recent term been extension continue greater At to hemolytic in patients the response ITP In follow not autoimmune most medium anemia, has reached duration study. extension months. safety was endpoint long was study XX. responder there met no and XX, by the the eight that's one in was signal. patient stage primary and XX% an week with continuing at Patients responding week additional

only signaling. study you and arthritis, investigational the into cytokine of in a response can a and pathways among IRAK I and candidate RXXX Finally, that receptor during immune to quarter. prevents as family innate inflammatory let critical gout inflammatory role activation IRAKX bit of moved rheumatoid response that receptor IL-X potent psoriasis, inflammatory in conditions receptors the others. we a RXXX Phase a is cytokine receptor bowel variety IRAKX Toll-like these and me TLR tell this about blocks inhibitor interleukin-X interleukin-X receptors The and play such family program and release selective of lead disease dysregulation toll-like and in-vitro. available response to to production

healthy The psoriasis, IRAKX/X active safety profile. volunteer ongoing. is so profile clean lupus, In such addition, and models result cohorts, first is The in disease our from linear with PK Phase gout. as multiple inflammatory arthritis, and I animal sclerosis RXXX the inhibitor in multiple a of

Additional planned. are multiple and dose cohorts single

will I for Dean financial Now, it back to pass review.

Dean Schorno

Anne-Marie. you, Thank

to I'd Slide quarter. highlights team from the to part First, here at the the Starting are extremely Rigel of XX, say business. am some like be excited transformational on our I in financial of point this

First, using products our recognize we when let the methodology me are our specialty delivered selling point that to revenue out distributors.

been commercial XX clinics, of XXXX, TAVALISSE. the to Slide, shipped second was in the expenses in to while $X.X as in product to costs million quarter of product $XXX,XXX million our recorded We bottles of and third channel sales. cost reported teams, of discounts, commercial $XX,XXX of estimated sales the quarter remain party those gross allowances the to For specialty $XX.X co-pay We product or of quarter our assistance in has about of of XXXX. rebates, as XXX product well our million resulting to Progressing sales chargebacks, of reported $X.X cost returns, of $XX.X related our adjustments. shipped sales. for bottles XXX which million the and at of second patients and second due next net were bottles of compared distribution personnel net and other those were TAVALISSE in end This net our of to distributors, gross-to-net second increased our XXXX total the X% of with primarily launch medical costs approximately quarter.

to We net $XX.X per the reported in quarter loss $X.XX total of increases XXXX. costs per compared $XX.X We or million $X.XX expect the a quarter continued and of our quarter-over-quarter in expenses. second net of a million second or loss share XXXX share in of

of offering XXXX, of During completed the XXXX. a including of quarter in May over underwritten the million Greenshoe the successful $XX million proceeds, in net second XX.X we of public with exercise shares

you, XXXX We Back to with continued the this of of investments We $XXX provide into runway expected million. Raul. quarter along XXXX and clinical with cash financing fourth quarter extend approximately our for will of term and commercial costs the their expansion short the programs. second certain ended

Raul Rodriguez

Thank you, Dean.

give Before plans. on update current I our collaboration wrap an up, you I and future like to

of with would the in European place commercialize European North in an collaborations; and Asian one, in would TAVALISSE commercialize Asian countries; fostamatinib partnership America is to that outside that Our partnership two other, put Japan the all strategy other major countries. major

expect half year We starting first be in to with XXXX. of next both place first of these the partnerships the in

Bristol-Myers by will The Squibb finding oncology. terminating in our was regimen update therapeutic been pre-clinical reason dosing be collaboration our and an window. an that to partnerships, have acceptable and informed current difficulty we As they primary

various trials cancers various progress. tumors. BerGenBio actual Sankyo different autoimmune methodologic our Aclaris in compound, result six licensed make forms with hair. clinical MDMX our and loss in inhibitor of and various was complete is conducting and DS-XXXXX also in inhibitor clinical solid trials lastly, And trials clinical stage conducting continue solid various clinical to is fostamatinib is with tumors. inhibitor methodologic disease a very partial or in JAK that of Daiichi and However, collaboration good areata conducting with alopecia

to results. business promising on announced strategy. conducted we Slide chronic program at you; like adult a and remind in are I'd delivering Phase one, Looking our ITP XX, III We

file TAVALISSE for first we NDA TAVALISSE also Our we And this indication and are are U.S. not first, the U.S. in our and first. then approval commercializing get ITP the we for

what treatment call. of So in on an you covered for the May, let end initial there need in helps just launch response Since chronic important TAVALISSE augment of this the me now build is at the working TAVALISSE medical we strategy our the significant summarize indicates for is well. One, ITP. medical ITP. need is approved and

Europe Prescriptions across physician, government is therapy ITP responses. change positive gaining fostamatinib so to and especially payer are and we Asia TAVALISSE great financial experience receiving in shows And payers. autoimmune in TAVALISSE by via of and are now lines and a commercial and execute potential are finally, working Physicians expand to indication position are We both potential on we strategy. are of TAVALISSE we working very covered believe partnerships strong are the we being patient expand treated. and to all this hemolytic And anemia. to another with

I'd the questions. that, to call would? turn like if to with So your you Operator,

Operator

you. question Thank Yang first from from your Jefferies. comes And Instructions] Kyung [Operator

open. Your line is

Kyung Yang

detailed very you thanks on for analysis the and Thank revenue TAVALISSE. much,

it's of where net sales you to of think booking? sales do launch end think overtime, compared stabilize that cycle, sorry of in obviously the would but do a product and very cost that sales So kind the are in are you - you to user early terms then you

Raul Rodriguez

Dean? Yeah, Okay.

Dean Schorno

Kyung. Hi,

of products about perspective, million we've or our of or So from reported growth to gross-to-net a $XXX,XXX XX%. adjustment growth net $X.X our on sales

XXX essentially to book that - me that revenue on that on a required book which we Let delivered. full the we basis bottles selling means we're

factors respect mix, as what government happen donut adjustment think well as will to we hole. as including of versus a the Medicare with variety need the we commercial, So to estimates of provide such

So see, gross-to-net therefore expect XX%. estimates overtime is will that the We all that and XX% again we believe slightly of adjustment normalize conservative an these below estimate. we been to

Kyung Yang

All a less are gone bottles, to end Okay. so And right. XXX the users, of you terms how XX%. shipped so user demand, have then in than about XX about end about that's

So your been would end do of quarters, normalized a you a think kind what when of have book overtime, couple user you net sales? demand a after

Raul Rodriguez

step well. take Maybe, just join in Dean and and small a initial let I Eldon a as

is demand patient grow roughly we in-channel this I to driven number. think We the number and to on continuing that expect full showed our overtime right but quarter from will fluctuate at And XX our demand - the is grow to is something the that expectation. week. that's

Dean Schorno

So, of noted in see We've comment the distribution revenue inventory I I'll you unit recognized volume. that the currently that details, call my bottles and on XXX it in there's our in as channel, distributors.

quarters term. don't number As on, material to roll at expect to near least in future we a see the that increase

As inventory Again, is see let end scales, increase, and in that business we know it of QX. at what quarters ahead number the our area we'll it level in could we think will future the that in the channel that is. you normalize but go that

Kyung Yang

Okay. And the last with question is on Aclaris. the the collaboration

So data milestone on target a you'd terms approved? comment had potential the Aclaris recently of agreement that as in of some what if alopecia. treatment you terms in your terms royalty a milestone, with financial financial as receive they well Can of in

Raul Rodriguez

some to they JAK put that. royalties make as do out data with progress we'll The get get we with collaborator, to June commensurate to inhibitor licensed we on are interim it. them again that licensed as I a and are them the initial program. We believe we program good the the on based they we progress pre-clinically, We terms we And very have good So, with that. first do molecule. get that very that - do the and commensurate And royalties clinical preclinical milestones. report deal in so

Kyung Yang

study? mentioned I milestone mean Phase the Okay. I that past, end payment in a II think you the at of there

Raul Rodriguez

that distant very might not I little a be think but beyond in it that.

yes. So,

Kyung Yang

Okay. Thank you.

Operator

Kim, from you. Do Capital question comes And Thank next your BMO Markets.

line open. is Your

Do Kim

is of there's sense guys and you the to the the from delays? afternoon, on the coverage kind have you delays, you for a are reimbursement, congrats seeing of that what On average reason do what said for and time Good the when pushback reimbursement launch. insurers approval

Eldon Mayer

Sure. Eldon. Hi, this is

referring which thing as first is the you're So as turnaround is think far to. I time what

looks. the that I think tracking. important be that's trying time are an and it's and the what will to we And analyzing something of early stage determine that at that that we're metric although launch, we means at this still how

So I this about to that point but we point. that at reveal don't at early metric talk that or this data want think

I that prescriptions that think we in may future. on week in on the a clearly time, of that we're will patients do four something over convert beginning have so the say don't to that we basis. And I through think I are did seeing are the a seeing it's there need so on emphasize good report have reimburse. not majority we we shipment would though the that is system timely again limited move are trial certainly although that to free program, for on patients

with far time your would think I the sure make actually as asking, you question - repeating it? just I understand I second As mind you're the

Do Kim

the reasons if was any? Yeah, or for delays or potential there coverage denials the

Eldon Mayer

process. through are known as an with I we working Yeah, exception think payers what's it's

the mentioned, engaging with I we XX and as are access gaining top So payers.

of time, it's And roughly a period. course in and a time middle will the year so launching of month take that usually six the

formal and and what formulary establish criteria with good we make doing PNT And for those working that coverage we're that is committee between access. they a so sure and when have now to payers have we

a normal So those ultimately a there to is and agreement that that's take longer. bit able And as an process exception come process payers expected. can to additive criterion an coverage with little we're on being formulary like again and until

with possible. many we're to quickly as are we and as process them interim as as communicating However, PBMs, to larger the determine and them with everything and of working move what well payers along

probably with but not manage the there basis. seeing payer well I they and along are also delays engaging payers think any So and We're of know per regional of as they're a them proportion are on way expected unusual. lives smaller we're many as a anything that

Do Kim

go Great. payer That's gross-to-net say comments mix? And it do that is it below helpful. primary the drive demand would or that would that on what the likely your XX%, mean are And for method just will, will factors all Dean, that to when prior you revenues period? stabilize you your transition a said be will XQ when - you in that in changes, sell-through

Dean Schorno

Yeah.

the So that the so is on gross-to-net mix. you element adjustment, the the biggest as suggest -

commercial our then and and and development XX/XX lower price mix and the at net if commercial mix So the set, think we're higher are obviously about basis, estimating about commercial On payers between price. payers those you Medicaid payers. government a and a a net Medicare the government program,

that that whole effects as biggest the will such donut the driver the as gross-to-net. mix, So as well also is element the

remaining quarter, with is big we on the the during the it my ended the distribution that to XXX so With clinic, sold our channel, again, So XXX in quarter let in-channel respect been that driver. say had me and again comment about were inventory. to patients that in in of inventory, XX normalizing bottles

do we go forward, at would about the we level inventory As in that XXX. expect remain that channel

a it become inventory both have patients overall in reporting to future volume will in revenue primarily will and of less be clinics bottles new our that from mix. we as quarters, shipped So factor and

Do Kim

Thanks my taking for it. questions. Got

Raul Rodriguez

Thank you, Do.

Operator

Wainwright. go H.C. Please Thank ahead. question your Pantginis Joseph you. And from next with comes

Joseph Pantginis

question. afternoon. the good taking guys, Thanks Hey

you data talked ongoing First, prepared the about coming about something, you regard I in during marketing you bit your I comments to clarify a on with can months, publishing that? elaborate little want more to believe

Raul Rodriguez

Presenting late then posters next year the presentations be And to some might more data well meeting our hope ITP for other year. ASCO conferences. example this much did year we and have we on at ER as there AIHA, like this as at

Joseph Pantginis

the Thank That's seeing for in you responded therapies, might with targeting is see initial you. you have currently? of the have some And the on not that prior later to are patients included even believe stage calls I mix Okay. stage guess well to example that then physicians patients described mention other mix responses say patients to obviously of earlier what that I be did initial patient regard helpful. curious level

Raul Rodriguez

Sure. one. I that can

We mix. are really seeing a very good

We to therapy we line earlier of as patients patients probably third, mostly fourth well. majority a see of and are we the are and significant that seeing at seeing the expected overall line later. is line later But number

a balanced We'd it's we're than by it's we but expect actually bit sampling way. so little a So good surprised see that little in better pretty to a that and anticipated. some of

I sign in of role physicians already point. that's a product this good earlier at think for the could a that see therapy have future lines very this that

Joseph Pantginis

So, that sign. if sure is you my not last question, yet. then I'm a good Thank and answer you can

like of if You as could even just you look right? curious pivotal are ongoing it's in goal though might what your AIHA, mentioned least list trial share ongoing FDA discussions for you a at a wish or of sort

Raul Rodriguez

Let AIHA me about the ask just I think it's a remind opportunities, let me we respond, you I to before tremendous - Anne-Marie opportunity. think

that driving currently important in of objective. is for success I'll FDA And and moving ask that's company flux. this a most to that the for indication it new and as to there's we forward medical AIHA with thing are TAVALISSE going which of to do out that one think beneficial patients and our in us tremendous address commercializing to is Anne-Marie part still that ask and is most figuring what that. if second ITP to But be verified are need I embedded specifically and approved next to the treatments

Anne-Marie Duliege

population which discussion matter the definition with the trial to ultimately the the of In into the is patient the the general, the of sample are to the primary getting the design population endpoint. patient don't that of ongoing We specifics FDA. will that key be and the enrolled exactly study size element of

Raul Rodriguez

comfortable things have terms be by feel cetera are patients be So, the summer and development. of time all that the estimate and numbers the are in the design certainly more that able we Day trial I to by we that the in and crisp think the we'll October end et of those and the still Analyst on that of much And our timeframes. of some in

Joseph Pantginis

a lot, guys. That's great. Thanks

Raul Rodriguez

you, Thank Joe.

Operator

next Piper Thank [Operator Raymond question our Chris And with you. Instructions] Jaffray. from France comes

Your line is open.

Christopher Raymond

and Hey, the on progress. thanks congrats guys

I to like You patient know thought be was guys question you supply. might be, don't think this I free a a free one be a month covered bottle this dumb but this, might going given every

you that's clarify bottles this drug. XX paying can patients of that's not Is just to So right, that free shipped correct? reimbursed

Raul Rodriguez

Chris. correct, That's

structured a we if there's lot the we've So an is, there pretty or so intron structured. delay it's way at request of in supply, program, a can looked physician the when closely the way guidelines, that's is access, way this patient the we structured the but

So in of know patients our small getting pretty that. you scheme, percentage

think but I that's on get access get also patients percentage on it's me, drug know not and that. that if large So to that reassuring to excuse need physicians encouraging, quickly they a you our we it's our provide can for know quickly customers, you -

Christopher Raymond

what were free was give as patients? of patients that that that at getting the was I to number required you That roll is, what range can independent might initial drug some sort over of

Raul Rodriguez

less what XX% was of than It's shipped.

Christopher Raymond

know any the label sense the on you question. you between, of the the question Okay, versus who people in do of mix patients, lines the next answered medics, of good. XX you had maybe a are off know And sense? I in a source right previous therapy, a tucks but then on right folks

Raul Rodriguez

why, I great we more. data mean got bit I it's recently. think analyze the that's a that's a data little of know You like just We part question that to Chris.

you all to time discuss see I to just saw. patience, a mix future yet. pretty haven't sift again So can means. and I have we you think the what across we it's the in love that have when that And really really I'd we visibility, all good enrollments know it tell analyze all to the time road had data

So The reliable will enrollments Rigel it you our is Care. that if is which coming hub data. to One

and history they a a require So something one case with require how they you the to and as make standard least part probably reimbursement prior know prioritization. many of a have therapy had that payers will sure process at

of them. We number get more we to may process, So course data high have in visibility later. that the of do a

now, hope that I have on So more answer that at time. another we question should for

Christopher Raymond

thanks. That's great,

Operator

Rodriguez questions at And to and remarks. further over like turn showing Raul to no queue. the I'd you. back this Thank further time, CEO, President in for call

Raul Rodriguez

Thank those you for and questions. thank you

more accomplish to patients remind PDSA from you life meeting get quarter my for what That to Support Association favorite financially valuable suffering to it Platelet the a was improving basis TAVALISSE weeks option. patients with we twentieth towards think ago, for began is meeting, attend treatments At PDSA ITP. to serious to we're in here. this Disorder this I'd it's trying achieve first time Cleveland conference before it's that. mostly provide like finish, new yearly a excitement So few from is and to ally And globally illnesses the real patients itself anniversary of on having and oriented meeting, because about I communicating the was this. patients. availability their a in there treatment rewarded very

number various in asked, finding option out substantial At I They product they and treatment good gratifying. that were the they and the sessions, hearing. a I TAVALISSE trying the XX over think doing, know very you hand what new but I they're breakout that enthusiasm amount of has years hearing patients they're responses that's that's we of how and doctors product those. anyone tried for on know The are don't think were is they first are from their a incredible. patients initial What well. raise from seeing

look the your for helping So our updates achieve much thank seeing regular Day time. for you give October. And progress. thank our us to So at you you in in so We upcoming Analyst I we'll wanted that you forward to weeks, on

Operator

your thank in conference. This program. today's and the for participation concludes Ladies you gentlemen,

now Everyone may have You day. a great disconnect.

Rigel Pharmaceuticals (RIGL) 8 Aug 182018 Q2 Earnings call transcript